Uncategorized Archives - Page 5 of 165

TuesdayAug 25, 2026 9:00 am

Nano-X Imaging Ltd. (NASDAQ: NNOX) Is ‘One to Watch’

The company combines proprietary imaging hardware, FDA-cleared AI applications, cloud software, radiology services and healthcare IT within an end-to-end platform spanning scan, analysis and interpretation. Nanox is expanding its commercial reach through its U.S. commercial activities and collaboration with healthcare organizations. First-quarter 2026 revenue increased to $4.3 million from $2.8 million in the prior-year period, with contributions from teleradiology, imaging systems, OEM services, AI, software and Health IT. Nanox has secured FDA clearance for Nanox.ARC, Nanox.ARC X and three Nanox.AI medical imaging solutions, while its commercial and clinical activities involve organizations including RadNet, Cedars-Sinai, Corewell Health and Brigham and Women’s…

MondayAug 24, 2026 9:00 am

VERAXA Biotech AG (NASDAQ: VRXA) Advances VXA-222 Cancer Program Beyond Discovery Phase

Following completion of the initial phase of its collaboration with OmniAb, VERAXA will engineer the final VXA-222 candidate and conduct the preclinical validation needed to determine the program’s next development steps. VXA-222 uses an “AND-gate” approach designed to recognize two tumor-associated antigens simultaneously before delivering its therapeutic payload. The company has separately filed its first patents related to its BiTAC-TCE and BiTAC-ADC platforms while expanding protection around antibody conjugation and payload technologies. The company is building a diversified oncology pipeline spanning bispecific T-cell engagers, ADCs, and other engineered antibody formats. VERAXA Biotech (NASDAQ: VRXA), an emerging leader in designing novel…

FridayAug 21, 2026 9:00 am

VERAXA Biotech AG (NASDAQ: VRXA) Builds Antibody-Based Cancer Pipeline Around Dual-Targeting Precision

VERAXA Biotech is changing how antibody-based therapies recognize and attack cancer cells, developing antibody-based cancer therapies with an emphasis on bispecific antibody-drug conjugates (“ADCs”) and T-cell engagers (“TCEs”). Its proprietary BiTAC platform uses a dual-targeting, “AND-gated” architecture designed to activate therapeutic effects preferentially at tumor sites. The company has advanced its lead BiTAC-TCE toward IND/CTA-enabling activities following cell-line development work and regulatory feedback from Germany’s Paul-Ehrlich-Institute. VERAXA’s VXA-222 bispecific ADC has moved beyond the initial discovery phase following completion of the antibody-discovery step with OmniAb. The company reported more than 50 granted owned or exclusively licensed patents across 26 patent…

WednesdayAug 19, 2026 10:30 am

Earth Science Tech Inc. (ETST) Continues Steady Growth with Acquisition of California-Based Compounding Pharmacy

Earth Science Tech, an expanding health-based holding company, recently announced the acquisition of Meduvo LLC, a compounding pharmacy that currently operates from a 2,000-square-foot facility in La Verne, California The acquisition grows the company’s network to 34 jurisdictions in the United States and establishes a strategic West Coast operational hub In addition to Meduvo, ETST also operates other compounding pharmacies through its specialized subsidiaries RxCompoundStore.com LLC (“RxCS”) and Mister Meds LLC Earth Science Tech (OTC: ETST), a strategic holding company in the healthcare, pharmacy, and telemedicine sector, recently acquired Meduvo LLC, a compounding pharmacy. Meduvo currently operates from a 2,000-square-foot…

WednesdayAug 19, 2026 9:00 am

Quantum BioPharma Ltd. (NASDAQ: QNTM) Advances Myelin-Protecting MS Therapy as Treatment Paradigm Evolves

MS drug development is increasingly expanding beyond controlling inflammation toward approaches designed to protect the nervous system and address mechanisms underlying progressive disability. Remyelination and protection of existing myelin remain major unmet needs in MS, as no approved therapy has established the ability to restore previously damaged myelin. Quantum BioPharma’s Lucid-MS is a patented new chemical entity designed to inhibit demyelination and protect myelin without suppressing the immune system. The U.S. FDA has cleared Quantum BioPharma to proceed with its planned phase 2 clinical trial of Lucid-MS in people with multiple sclerosis. Multiple sclerosis (“MS”) treatment has traditionally focused on…

TuesdayAug 18, 2026 10:00 am

Researchers Identify a Protein That Could Be Targeted in Glioblastoma Therapy

Glioblastoma is very difficult to treat because it quickly adapts and evolves to become resistant to existing treatments indicated for brain cancers. Now, scientists have found a protein on this cancer’s cells that could be targeted in order to make the cancer more vulnerable to the treatments administered to combat this deadly malignancy. The discovery was made by researchers based at the Comprehensive Cancer Center at Ohio State University. The findings of this preclinical study appeared in the journal Cancer Letters. The team wanted to find a way to make existing treatments like chemotherapy and radiotherapy more effective against this…

FridayAug 14, 2026 10:30 am

Earth Science Tech Inc. (ETST) Seeks to Implement a Unified Strategy to Unlock True Market Value and Support Shareholders

Earth Science Tech seeks to implement a unified strategy aimed at maximizing shareholder value, resolving structural hurdles, and elevating corporate governance The company will hold a virtual annual meeting on August 31, 2026, during which shareholders will vote on key initiatives that will position ETST for an uplisting to a higher-tier exchange, eliminate the structural barriers that hinder the infusion of institutional capital, and prevent stock dilution These initiatives are informed by extensive dialogue between shareholders and management leading to a consensus that the company’s current market valuation simply does not accurately reflect its financial success or future potential The…

FridayAug 14, 2026 9:45 am

Regentis Biomaterials Ltd. (NYSE American: RGNT) Moves GelrinC Along Parallel US Clinical and European Commercial Tracks

Regentis has passed 50% enrollment in the pivotal Phase III SAGE study of GelrinC, with recruitment completion targeted for the third quarter of 2026 and a PMA process expected to begin by the end of 2027. FDA approved a single-arm protocol using a historical microfracture control data package the company owns, and Regentis reports that the first 40 patients closely match that control group. In Europe, where GelrinC already holds CE Mark approval, surgeon training began in the third quarter of 2026 at Humanitas Research Hospital in Milan, supported by an expanded clinical site network and a newly approved manufacturing…

ThursdayAug 13, 2026 9:00 am

Regentis Biomaterials Ltd. (NYSE American: RGNT) Builds a Manufacturing and Intellectual Property Powerhouse for the Global Cartilage Repair Market

A new Japanese patent allowance follows a recent such US patent grant, strengthens protection around the organic solvent-free manufacturing process and ready-to-use liquid formulation behind GelrinC, extending the company’s intellectual property footprint into one of the world’s largest cartilage-repair markets. The process delivers a 5-fold increase in yield along with simplified production and commercial scalability, the manufacturing economics needed to make an off-the-shelf cartilage product commercially viable at scale. The milestone lands as Regentis advances European commercialization and passes the halfway mark in enrollment for its pivotal U.S. trial. Aging populations are pushing joint disease higher on the orthopedic agenda,…

WednesdayAug 12, 2026 9:00 am

Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) Targets Disability Drivers Beyond Relapse Rates in Multiple Sclerosis

Disseminated on behalf of Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) and may include paid advertising. Researchers recognize that a large share of long-term disability accumulates independent of relapses altogether, a phenomenon researchers call progression independent of relapse activity. That shift has forced researchers to look at what is actually driving PIRA. A major suspect is chronic active lesions, sometimes called smoldering or mixed active-inactive lesions. Rather than broadly suppressing the immune system, Quantum BioPharma’s Lucid-MS is designed to inhibit myelin degradation, preserve myelin and support functional recovery. Multiple sclerosis is quietly shifting how drugmakers define success. Instead of judging a therapy mainly by…

News and publishing service for medical and biotechnology related companies

Contact us: 512.354.7000

Category: Uncategorized

Nano-X Imaging Ltd. (NASDAQ: NNOX) Is ‘One to Watch’

VERAXA Biotech AG (NASDAQ: VRXA) Advances VXA-222 Cancer Program Beyond Discovery Phase

VERAXA Biotech AG (NASDAQ: VRXA) Builds Antibody-Based Cancer Pipeline Around Dual-Targeting Precision

Earth Science Tech Inc. (ETST) Continues Steady Growth with Acquisition of California-Based Compounding Pharmacy

Quantum BioPharma Ltd. (NASDAQ: QNTM) Advances Myelin-Protecting MS Therapy as Treatment Paradigm Evolves

Researchers Identify a Protein That Could Be Targeted in Glioblastoma Therapy

Earth Science Tech Inc. (ETST) Seeks to Implement a Unified Strategy to Unlock True Market Value and Support Shareholders

Regentis Biomaterials Ltd. (NYSE American: RGNT) Moves GelrinC Along Parallel US Clinical and European Commercial Tracks

Regentis Biomaterials Ltd. (NYSE American: RGNT) Builds a Manufacturing and Intellectual Property Powerhouse for the Global Cartilage Repair Market

Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) Targets Disability Drivers Beyond Relapse Rates in Multiple Sclerosis

Official NewsWire Relationships

BioMedWire Currently Accepts

BioMedWire

Company Search

Site Search